Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules, including various cytokines or chemokines. Here, we have deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ylösmäki, Erkko, Ylösmäki, Leena, Fusciello, Manlio, Martins, Beatriz, Ahokas, Petra, Cojoc, Hanne, Uoti, Arttu, Feola, Sara, Kreutzman, Anna, Ranki, Tuuli, Karbach, Julia, Viitala, Tapani, Priha, Petri, Jäger, Elke, Pesonen, Sari, Cerullo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917457/
https://www.ncbi.nlm.nih.gov/pubmed/33718594
http://dx.doi.org/10.1016/j.omto.2021.02.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917457/
https://www.ncbi.nlm.nih.gov/pubmed/33718594
http://dx.doi.org/10.1016/j.omto.2021.02.006

Ejemplares similares